| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Daniela Calandrella, Angelo Antonin. Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease. Parkinsonism & related disorders. vol 18 Suppl 1. 2012-08-27. PMID:22166407. |
all studies comparing levodopa versus dopamine agonist early therapy indicate that initiation with agonists is associated with a reduced risk of motor complications - in particular, dyskinesias - possibly because agonists' longer half-lives provide continuous dopaminergic delivery. |
2012-08-27 |
2023-08-12 |
Not clear |
| A Jon Stoess. Neuroimaging in Parkinson's disease: from pathology to diagnosis. Parkinsonism & related disorders. vol 18 Suppl 1. 2012-08-27. PMID:22166455. |
functional imaging using dopaminergic tracers with either pet or spect can identify dopamine deficiency but may not reliably differentiate between pd and other akinetic-rigid disorders. |
2012-08-27 |
2023-08-12 |
human |
| Fu Xu, Xiuli Chang, Dan Lou, Qing Wu, Zhijun Zho. Chlorpyrifos exposure causes alternation in dopamine metabolism in PC12 cells. Toxicology mechanisms and methods. vol 22. issue 4. 2012-08-27. PMID:22356570. |
to investigate the effects of cpf on dopaminergic pathway, the dopamine content, gene expression of catechol-o-methyl- transferase (comt), vesicular monoamine transporter-2 (vmat-2), and monoamine oxidase (mao) and its activity in pc12 cells exposed to cpf was determined. |
2012-08-27 |
2023-08-12 |
Not clear |
| Beatriz De la Casa-Fages, Francisco Granda. Dopamine dysregulation syndrome and deep brain stimulation of the subthalamic nucleus in Parkinson's disease. Neurology research international. vol 2011. 2012-08-23. PMID:22135744. |
dopamine dysregulation syndrome is a complication of the dopaminergic treatment in parkinson's disease that may be very disabling due to the negative impact that compulsive medication use may have on patients' social, psychological, and physical functioning. |
2012-08-23 |
2023-08-12 |
Not clear |
| A Machado, A J Herrera, J L Venero, M Santiago, R M de Pablos, R F Villarán, A M Espinosa-Oliva, S Argüelles, M Sarmiento, M J Delgado-Cortés, R Mauriño, J Can. Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons. ISRN neurology. vol 2011. 2012-08-23. PMID:22389821. |
the special sensitivity of dopaminergic neurons seems to be related to the endogenous dopaminergic content, since it is overcome by dopamine depletion. |
2012-08-23 |
2023-08-12 |
Not clear |
| Lane J Wallace, Jessica S Traege. Dopac distribution and regulation in striatal dopaminergic varicosities and extracellular space. Synapse (New York, N.Y.). vol 66. issue 2. 2012-08-22. PMID:21987292. |
dopac, the major intermediate metabolite of dopamine, is found in the cytosolic compartment of dopaminergic terminals/varicosities and in the extracellular space. |
2012-08-22 |
2023-08-12 |
Not clear |
| Lane J Wallace, Jessica S Traege. Dopac distribution and regulation in striatal dopaminergic varicosities and extracellular space. Synapse (New York, N.Y.). vol 66. issue 2. 2012-08-22. PMID:21987292. |
on the basis of literature data supporting such a concept, we hypothesize a dopac synthesis/secretory complex producing extracellular dopac and use a computational simulation model of dopaminergic varicosities to estimate the distribution of dopac between cytosolic and extracellular compartments, amount of newly synthesized dopamine entering the dopac synthesis/secretory complex, and potential regulatory processes in the complex. |
2012-08-22 |
2023-08-12 |
Not clear |
| Evangelia Giza, Dimitrios Fotiou, Sevasti Bostantjopoulou, Zoe Katsarou, George Gerasimou, Anna Gotzamani-Psarrakou, Anna Karlovasito. Pupillometry and 123I-DaTSCAN imaging in Parkinson's disease: a comparison study. The International journal of neuroscience. vol 122. issue 1. 2012-08-21. PMID:21883027. |
the purpose of this study was the evaluation of pupil light reflex (plr) in patients with parkinson's disease (pd) by using a modern pupillometry system and the investigation of its potential relationship with dopamine transporter imaging (datscan), which is an objective method for the evaluation of presynaptic dopaminergic system. |
2012-08-21 |
2023-08-12 |
Not clear |
| Senthilkumar S Karuppagounder, Manuj Ahuja, Manal Buabeid, Koodeswaran Parameshwaran, Engy Abdel-Rehman, Vishnu Suppiramaniam, Muralikrishanan Dhanasekara. Investigate the chronic neurotoxic effects of diquat. Neurochemical research. vol 37. issue 5. 2012-08-20. PMID:22331545. |
these data indicate that, despite the apparent structural similarity to other dopaminergic neurotoxins, diquat did not exert severe deleterious effects on dopamine neurons in a manner that is unique to rotenone and mptp. |
2012-08-20 |
2023-08-12 |
mouse |
| Fabienne Stephanie Sprenger, Klaus Seppi, Werner Poew. Drug safety evaluation of rotigotine. Expert opinion on drug safety. vol 11. issue 3. 2012-08-14. PMID:22468676. |
randomized, double-blind, placebo-controlled, as well as open-label studies were conducted in ipd and rls patients to evaluate the efficacy, tolerability and safety of rotigotine in dosages up to 16 mg/24 h. overall, these trials have shown that rotigotine has a similar adverse event (ae) profile as other non-ergolinic dopamine agonists such as pramipexole or ropinirole, inducing typical dopaminergic effects like nausea, daytime somnolence, peripheral edema or impulse control disorders. |
2012-08-14 |
2023-08-12 |
Not clear |
| C Venkateshappa, G Harish, Rajeswara Babu Mythri, Anita Mahadevan, M M Srinivas Bharath, S K Shanka. Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson's disease. Neurochemical research. vol 37. issue 2. 2012-08-13. PMID:21971758. |
parkinson's disease (pd) is characterized by selective degeneration and loss of dopaminergic neurons in the substantia nigra (sn) of the ventral mid brain leading to dopamine depletion in the striatum. |
2012-08-13 |
2023-08-12 |
human |
| Julian Lim, Richard Ebstein, Chun-Yu Tse, Mikhail Monakhov, Poh San Lai, David F Dinges, Kenneth Kwo. Dopaminergic polymorphisms associated with time-on-task declines and fatigue in the Psychomotor Vigilance Test. PloS one. vol 7. issue 3. 2012-08-13. PMID:22438994. |
we posit that the dopamine transporter and comt genes exert their effects by increasing dopaminergic tone, which may induce long-term changes in the prefrontal cortex, an important mediator of sustained attention. |
2012-08-13 |
2023-08-12 |
human |
| Simon Allard, Varin Gosein, A Claudio Cuello, A Ribeiro-da-Silv. Changes with aging in the dopaminergic and noradrenergic innervation of rat neocortex. Neurobiology of aging. vol 32. issue 12. 2012-08-08. PMID:20096955. |
although neuromodulation by dopamine and noradrenaline in the cortex is known to be important for proper cognitive function, little is known on how cortical noradrenergic and dopaminergic presynaptic boutons are affected in normal aging. |
2012-08-08 |
2023-08-12 |
rat |
| Simon Allard, Varin Gosein, A Claudio Cuello, A Ribeiro-da-Silv. Changes with aging in the dopaminergic and noradrenergic innervation of rat neocortex. Neurobiology of aging. vol 32. issue 12. 2012-08-08. PMID:20096955. |
following the behavioral characterization, the animals were sacrificed and the cortical tissue was processed for immunofluorescence using antibodies directed against tyrosine hydroxylase (th) and dopamine beta-hydroxylase (dbh) to detect and discriminate noradrenergic and dopaminergic varicosities. |
2012-08-08 |
2023-08-12 |
rat |
| Ariel Rokem, Ayelet N Landau, William Prinzmetal, Deanna L Wallace, Michael A Silver, Mark D'Esposit. Modulation of inhibition of return by the dopamine D2 receptor agonist bromocriptine depends on individual DAT1 genotype. Cerebral cortex (New York, N.Y. : 1991). vol 22. issue 5. 2012-08-06. PMID:21799208. |
ior depends on striatal dopamine (da) levels: it varies with different alleles of the da transporter gene dat1 and is reduced in patients with parkinson's disease, a disease characterized by reduced striatal dopaminergic transmission. |
2012-08-06 |
2023-08-12 |
human |
| Yukio Ago, Toshiyuki Kawasaki, Tetsuaki Nashida, Yuki Ota, Yana Cong, Mari Kitamoto, Teisuke Takahashi, Kazuhiro Takuma, Toshio Matsud. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease. Neuropharmacology. vol 61. issue 8. 2012-08-01. PMID:21903118. |
sea0400 protected against the dopaminergic neurotoxicity (determined by dopamine levels in the midbrain and striatum, tyrosine hydroxylase immunoreactivity in the substantia nigra and striatum, striatal dopamine release, and motor deficits) in mptp-treated mice. |
2012-08-01 |
2023-08-12 |
mouse |
| Shu-Ling Liang, Jenn-Tser Pa. An endogenous dopaminergic tone acting on dopamine D3 receptors may be involved in diurnal changes of tuberoinfundibular dopaminergic neuron activity and prolactin secretion in estrogen-primed ovariectomized rats. Brain research bulletin. vol 87. issue 2-3. 2012-08-01. PMID:22155687. |
an endogenous dopaminergic tone acting on dopamine d3 receptors may be involved in diurnal changes of tuberoinfundibular dopaminergic neuron activity and prolactin secretion in estrogen-primed ovariectomized rats. |
2012-08-01 |
2023-08-12 |
rat |
| Mireille Basselin, Epolia Ramadan, Stanley I Rapopor. Imaging brain signal transduction and metabolism via arachidonic and docosahexaenoic acid in animals and humans. Brain research bulletin. vol 87. issue 2-3. 2012-08-01. PMID:22178644. |
we have employed our method to image and quantify effects of mood stabilizers on brain aa/dha incorporation during neurotransmission by muscarinic m(1,3,5), serotonergic 5-ht(2a/2c), dopaminergic d(2)-like (d(2), d(3), d(4)) or glutamatergic n-methyl-d-aspartic acid (nmda) receptors, and effects of inhibition of acetylcholinesterase, of selective serotonin and dopamine reuptake transporter inhibitors, of neuroinflammation (hiv-1 and lipopolysaccharide) and excitotoxicity, and in genetically modified rodents. |
2012-08-01 |
2023-08-12 |
human |
| Meret Nora Gaugler, Ozgur Genc, Wojciech Bobela, Safa Mohanna, Mustafa Taleb Ardah, Omar Mukhtar El-Agnaf, Marco Cantoni, Jean-Charles Bensadoun, Ralf Schneggenburger, Graham W Knott, Patrick Aebischer, Bernard Laurent Schneide. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta neuropathologica. vol 123. issue 5. 2012-08-01. PMID:22361813. |
wild-type α-syn causes a reduction of dopamine release in the striatum that exceeds the loss of dopaminergic neurons, axonal fibers, and the reduction in total dopamine. |
2012-08-01 |
2023-08-12 |
human |
| Meret Nora Gaugler, Ozgur Genc, Wojciech Bobela, Safa Mohanna, Mustafa Taleb Ardah, Omar Mukhtar El-Agnaf, Marco Cantoni, Jean-Charles Bensadoun, Ralf Schneggenburger, Graham W Knott, Patrick Aebischer, Bernard Laurent Schneide. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta neuropathologica. vol 123. issue 5. 2012-08-01. PMID:22361813. |
at the ultrastructural level, the reduced dopamine release corresponds to a decreased density of dopaminergic vesicles and synaptic contacts in striatal terminals. |
2012-08-01 |
2023-08-12 |
human |